Brazil's Pharmaceutical Market To Approach $30B By 2021, Says GlobalData

The Brazilian pharmaceutical market is set to grow from $25.3B in 2016 to $29.9B in 2021, representing a compound annual growth rate of 3.5%, according to research and consulting firm GlobalData.

The company’s latest report states that Brazil is one of the most attractive and promising pharmaceutical markets in the world, with all major global pharmaceutical companies operating in the country. Changing demographics are a key driver of the Brazilian pharmaceutical space, as a growing population of elderly citizens is likely to increase the incidence of chronic and lifestyle diseases. When combined with the availability of universal healthcare and advancements in pharmaceutical and medical technology, this is likely to drive demand for healthcare services.

Brazil’s overall health expenditure is also expected to grow through 2018, supported by increased investments in the country’s universal and free public healthcare system, in line with the government’s initiatives to improve access to health services and pharmaceuticals among underserved parts of the population. This upward trend in health spending should have a positive impact on pharmaceutical sales and provide substantial opportunities for companies.

Local pharmaceutical companies are also seeing improved market opportunities. Traditionally, Brazil’s pharmaceuticals space has remained largely reliant on imports, with its biotechnology sector highly dependent on imported raw materials and active ingredients for generic drugs. Government initiatives such as the Growth Acceleration Program and the Greater Brazil Plan were introduced to increase domestic production. The former is focused on modernizing public infrastructure, while the latter encourages local production of innovative drugs and promotes public-private partnerships in the form of technology transfer to public pharma laboratories for the development of higher-priced biosimilars.

• Information based on GlobalData’s report: CountryFocus: Healthcare, Regulatory and Reimbursement Landscape – Brazil.
• This report was built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis conducted by GlobalData’s team of industry experts.

About GlobalData
4,000 of the world’s largest companies, including over 70% of FTSE 100 and 60% of Fortune 100 companies, make more timely and better business decisions thanks to GlobalData’s unique data, expert analysis and innovative solutions, all in one platform. GlobalData’s mission is to help our clients decode the future to be more successful and innovative across a range of industries, including the healthcare, consumer, retail, financial, technology and professional services sectors.